TY - JOUR T1 - [Potential antiviral therapeutics for 2019 Novel Coronavirus]. AU - Li,H, AU - Wang,Y M, AU - Xu,J Y, AU - Cao,B, Y1 - 2020/02/05/ PY - 2020/2/6/entrez PY - 2020/2/6/pubmed PY - 2020/2/6/medline KW - 2019 novel coronavirus KW - Antiviral therapy KW - Infection SP - E002 EP - E002 JF - Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases JO - Zhonghua Jie He He Hu Xi Za Zhi VL - 43 IS - 0 N2 - The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials. SN - 1001-0939 UR - https://www.unboundmedicine.com/medline/citation/32023685/[Potential_antiviral_therapeutics_for_2019_Novel_Coronavirus]_ DB - PRIME DP - Unbound Medicine ER -